MTNB Matinas BioPharma Holdings Inc

Price (delayed)

$0.1657

Market cap

$41.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.12

Enterprise value

$43.89M

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has ...

Highlights
Matinas BioPharma Holdings's debt has decreased by 15% YoY and by 4.4% QoQ
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Matinas BioPharma Holdings's revenue has plunged by 100% from the previous quarter and by 100% YoY

Key stats

What are the main financial stats of MTNB
Market
Shares outstanding
250.82M
Market cap
$41.56M
Enterprise value
$43.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$23.25M
EBITDA
-$22.3M
Free cash flow
-$17.18M
Per share
EPS
-$0.12
Free cash flow per share
-$0.08
Book value per share
$0.07
Revenue per share
$0
TBVPS
$0.08
Balance sheet
Total assets
$19.61M
Total liabilities
$5.05M
Debt
$3.4M
Equity
$14.56M
Working capital
$8.29M
Liquidity
Debt to equity
0.23
Current ratio
5.15
Quick ratio
4.08
Net debt/EBITDA
-0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-85.7%
Return on equity
-109.7%
Return on invested capital
-109.1%
Return on capital employed
-132%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MTNB stock price

How has the Matinas BioPharma Holdings stock price performed over time
Intraday
3.56%
1 week
-7.94%
1 month
3.56%
1 year
-58.58%
YTD
-23.36%
QTD
3.56%

Financial performance

How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.08M
Net income
-$23.25M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Matinas BioPharma Holdings's revenue has plunged by 100% from the previous quarter and by 100% YoY
The company's net income fell by 13% YoY
The operating income has contracted by 7% YoY

Growth

What is Matinas BioPharma Holdings's growth rate over time

Valuation

What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
2.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 9% from the previous quarter and by 9% YoY
The company's equity has shrunk by 55% YoY and by 24% QoQ
The stock's price to book (P/B) is 31% less than its 5-year quarterly average of 3.5 and 7% less than its last 4 quarters average of 2.6
Matinas BioPharma Holdings's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Matinas BioPharma Holdings business performance
The ROE has dropped by 101% year-on-year and by 23% since the previous quarter
The return on assets has dropped by 91% year-on-year and by 19% since the previous quarter
Matinas BioPharma Holdings's ROIC has plunged by 91% YoY and by 19% from the previous quarter

Dividends

What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MTNB.

Financial health

How did Matinas BioPharma Holdings financials performed over time
The company's quick ratio has shrunk by 69% YoY and by 23% QoQ
MTNB's current ratio has dropped by 65% year-on-year and by 13% since the previous quarter
Matinas BioPharma Holdings's debt is 77% lower than its equity
The company's debt to equity has surged by 92% YoY and by 28% QoQ
The company's equity has shrunk by 55% YoY and by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.